Petra Steinacker

List of Publications by Year
in descending order

57	3,002	172207	168136
papers	citations	29 h-index	53 g-index

58	58	58	3863
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2015-311387.	0.9	207
2	Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Annals of Neurology, 2016, 79, 152-158.	2.8	188
3	TDP-43 in Cerebrospinal Fluid of Patients With Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Archives of Neurology, 2008, 65, 1481.	4.9	186
4	Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 157-164.	0.9	174
5	Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimerâ€™s Disease and Correlates with Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 67, 481-488.	1.2	171
6	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology, 2018, 90, e22-e30.	1.5	148
7	Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 4-10.	0.9	96
8	Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimerâ€²s and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies. Molecular and Cellular Proteomics, 2016, 15, 3126-3138.	2.5	92
9	Polyâ€<scp>GP</scp> in cerebrospinal fluid links C9orf72â€associated dipeptide repeat expression to the asymptomatic phase of <scp>ALS</scp>/<scp>FTD</scp>. EMBO Molecular Medicine, 2017, 9, 859-868.	3.3	90
10	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 239-247.	0.9	89
11	CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. Alzheimer's Research and Therapy, 2020, 12, 2.	3.0	86
12	14-3-3 proteins in neurodegeneration. Seminars in Cell and Developmental Biology, 2011, 22, 696-704.	2.3	85
13	Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology, 2018, 91, e1390-e1401.	1.5	85
14	Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 404-413.	1.1	84
15	Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Scientific Reports, 2016, 6, 38737.	1.6	81
16	Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. Journal of Psychiatric Research, 2019, 113, 137-140.	1.5	81
17	Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology, 2017, 88, 961-969.	1.5	73
18	Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 112-119.	1.1	63

#	Article	IF	Citations
19	Protein biomarkers in Parkinson's disease: Focus on cerebrospinal fluid markers and synaptic proteins. Movement Disorders, 2016, 31, 848-860.	2.2	52
20	Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen. Journal of Neurology, 2020, 267, 36-44.	1.8	47
21	Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimerâ€™s Disease. Journal of Proteome Research, 2020, 19, 1310-1318.	1.8	43
22	Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641984605.	1.5	41
23	Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldtâ€“Jakob disease. Proteomics, 2010, 10, 81-89.	1.3	39
24	Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 68-74.	0.9	39
25	Biomarkers for diseases with TDP-43 pathology. Molecular and Cellular Neurosciences, 2019, 97, 43-59.	1.0	38
26	Neuroprotective Function of Cellular Prion Protein in a Mouse Model of Amyotrophic Lateral Sclerosis. American Journal of Pathology, 2010, 176, 1409-1420.	1.9	37
27	Soluble Beta-Amyloid Precursor Protein Is Related to Disease Progression in Amyotrophic Lateral Sclerosis. PLoS ONE, 2011, 6, e23600.	1.1	36
28	Glial fibrillary acidic protein as blood biomarker for differential diagnosis and severity of major depressive disorder. Journal of Psychiatric Research, 2021, 144, 54-58.	1.5	34
29	Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 503-511.	0.9	33
30	Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimerâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 349-356.	0.9	31
31	Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis. Expert Review of Proteomics, 2017, 14, 769-777.	1.3	27
32	Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Journal of Neural Transmission, 2009, 116, 1169-1178.	1.4	26
33	Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update. Journal of Neurochemistry, 2016, 138, 184-192.	2.1	26
34	Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD. Journal of Neural Transmission, 2016, 123, 289-296.	1.4	26
35	Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies. Expert Review of Proteomics, 2017, 14, 499-514.	1.3	26
36	Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration. Journal of Neural Transmission, 2022, 129, 207-230.	1.4	26

#	Article	IF	Citations
37	Modified serpinA1 as risk marker for Parkinsonâ€™s disease dementia: Analysis of baseline data. Scientific Reports, 2016, 6, 26145.	1.6	24
38	Comparison of Internal Standard Approaches for SRM Analysis of Alpha-Synuclein in Cerebrospinal Fluid. Journal of Proteome Research, 2018, 17, 516-523.	1.8	23
39	Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: Current status and future perspectives. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 757-768.	1.1	21
40	Serum GFAP differentiates Alzheimerâ€™s disease from frontotemporal dementia and predicts MCI-to-dementia conversion. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 659-667.	0.9	21
41	Proteomic analysis reveals a biosignature of decreased synaptic protein in cerebrospinal fluid of major depressive disorder. Translational Psychiatry, 2020, 10, 144.	2.4	20
42	Serum neurofilament light chain (NFL) remains unchanged during electroconvulsive therapy. World Journal of Biological Psychiatry, 2020, 21, 148-154.	1.3	18
43	Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials. Translational Neurodegeneration, 2021, 10, 31.	3.6	18
44	Aggregated Î±-Synuclein Increases SOD1 Oligomerization in a Mouse Model of Amyotrophic Lateral Sclerosis. American Journal of Pathology, 2016, 186, 2152-2161.	1.9	17
45	CSF SerpinA1 in Creutzfeldtâ€“Jakob disease and frontotemporal lobar degeneration. Annals of Clinical and Translational Neurology, 2020, 7, 191-199.	1.7	16
46	A multi-center study of neurofilament assay reliability and inter-laboratory variability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 452-458.	1.1	15
47	Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 276-286.	1.1	14
48	Detection of intrathecal immunoglobulin G synthesis by capillary isoelectric focusing immunoassay in oligoclonal band negative multiple sclerosis. Journal of Neurology, 2016, 263, 954-960.	1.8	13
49	Cerebrospinal Fluid Levels of Prodynorphinâ€Derived Peptides are Decreased in Huntington's Disease. Movement Disorders, 2021, 36, 492-497.	2.2	12
50	Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy. Orphanet Journal of Rare Diseases, 2021, 16, 330.	1.2	12
51	Blood Î²-Synuclein and Neurofilament Light Chain During the Course of Prion Disease. Neurology, 2022, , 10.1212/WNL.0000000000200002.	1.5	11
52	ERK2 is Increased in Cerebrospinal Fluid of Creutzfeldt-Jakob Disease Patients. Journal of Alzheimer's Disease, 2010, 22, 119-128.	1.2	9
53	Serum <scp>Betaâ€Synuclein</scp> Is Higher in Down Syndrome and Precedes Rise of <scp>pTau181</scp>. Annals of Neurology, 2022, 92, 6-10.	2.8	9
54	CSF Ubiquitin Levels Are Higher in Alzheimerâ€™s Disease than in Frontotemporal Dementia and Reflect the Molecular Subtype in Prion Disease. Biomolecules, 2020, 10, 497.	1.8	8

#	Article	IF	Citations
55	Chromogranin A levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurobiology of Aging, 2018, 67, 21-22.	1.5	6
56	S-ketamine induces acute changes in the proteome of the mouse amygdala. Journal of Proteomics, 2020, 216, 103679.	1.2	6
57	Recent biomarker approaches in the diagnosis of frontotemporal lobar degeneration/Neurochemische AnsÃtze in der Diagnose der Frontotemporalen LobÃrdegeneration. Laboratoriums Medizin, 2012, 36, .	0.1	1